Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in GeneDx and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investor ...

Core Viewpoint - DJS Law Group is investigating Agilon Health, Inc. for potential violations of securities laws following significant leadership changes and a withdrawal of earnings guidance, which led to a sharp decline in the company's stock price [1][2]. Investigation Details - The investigation centers on whether Agilon made misleading statements or failed to disclose critical information to investors [2]. - On August 4, 2025, Agilon announced the resignation of President, CEO, and Board Director Steven Sell, which coincided with the release of its second quarter 2025 earnings results [2]. - Agilon also withdrew its previous full year 2025 earnings guidance, resulting in a more than 27% drop in shares during after-hours trading [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Petco Health and Wellness Company, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 14, 2021, and June 5, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related advantages were not sustainable and that its business model, which focuses on premium pet food, was overstated [2] - It is alleged that the defendants downplayed the severity of issues affecting Petco's business and the necessary changes to address these issues, which could negatively impact comparable sales [2] - The lawsuit asserts that the defendants misrepresented Petco's ability to achieve sustainable and profitable growth, leading to materially false and misleading public statements [2] Group 2: Next Steps for Investors - Investors who suffered losses in Petco during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of Duolingo investors regarding potential securities fraud or unlawful business practices by the company and its officers [1] - JMP Securities has lowered its price target for Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [3] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 on July 28, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case, which is currently pending in the U.S. District Court for the Central District of California under the caption Makaveev v. RxSight, Inc., et al. [2]. Financial Performance - The company experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite claims of strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lineage, Inc. ("Lineage, Inc." or the "Company") (NASDAQ: LINE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lineage, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial ...

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Flywire Corporation ("Flywire Corporation" or the "Company") (NASDAQ: FLYW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Flywire Corporation investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP investors who were adversely affected by alleged securities fraud between September 27, 2023 and January 27, 2025. Fo ...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Flywire Corporation ("Flywire Corporation" or the "Company") (NASDAQ: FLYW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Flywire Corporation investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fly ...